دانلود کتاب درمان های ترمیمی در بهبود سکته مغزی ایسکمیک

Stroke is a leading cause of death and disability worldwide. Globally, one in four people over age 25 will have a stroke in their lifetime, and there are over 13.7 million new strokes each year (Lindsay et al. 2019). Alarmingly, the incidence of stroke in people of working age (under 60 years old) has risen. Despite development of recanalization therapies, the number of stroke survivors is increasing with over 80 million people currently living with stroke globally. Almost all live with poststroke complications, such as motor deficits and cognitive impairment, which may impede their ability to carry out activities of daily living. Therefore, it is necessary to develop new therapeutic strategies to improve functional outcomes after stroke. Over the last few decades, major attention has been invested in neuroprotective therapies, which are designed to prevent or reduce cell death from ischemia. Initial preclinical studies demonstrated several drugs are effective for treating stroke in animal models; however, subsequent clinical trials have been disappointing, and none of the agents has proven effective in patients (O’Collins et al. 2005, 2017). Recently, neurorestoration has become a topic of interest since it was reported that the brain has the capability to repair itself after injury. The development of new therapeutic strategies to improve neurological function by enhancing the endogenous capacity for neurorestorative processes in the stroke damaged brain may help stroke patients with chronic disabilities.